A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors

Journal of Immunotherapy

Volumn 22, Issue 2, 1999, Pages 155-165

  Khleif, Samir N ^a   Abrams, Scott I ^b   Hamilton, J Michael ^a   Bergmann Leitner, Elke ^b   Chen, Alice ^a   Bastian, Anne ^a   Bernstein, Sarah ^a   Chung, Yoomie ^b   Allegra, Carmen J ^a   Schlom, Jeffrey ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ras oncogene mutations; Ras peptides; Ras vaccination

Indexed keywords

PHOSPHORYL LIPID A; RAS PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE MUTATION; HUMAN; IMMUNOSTIMULATION; ONCOGENE RAS; PRIORITY JOURNAL; SOLID TUMOR; VACCINATION;

ADULT; AGED; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MUTATION; NEOPLASMS; RAS PROTEINS; VACCINATION;

EID: 0032975450     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199903000-00007     Document Type: Article

References (34)

1. Bos JL, Fearon ER, Hamilton SR, et al. Prevelence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
2. Satoh T, Kaziro Y. Ras in signal transduction. Semin Cancer Biol 1992:3:169-177.
3. Grand RJA, Owen D. The biochemistry of ras p21. Biochemistry 1991;279:609-31.
4. Firuban RH, van Mansfeld AD. Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the humanpancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993:143:545-54.
5. Li ZH, Weiss SM, Shibata D. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994;144:303-9.
6. Breivik J, Mehling G. Spurkland A, Rognum TO, Gaudernack G. K-ras mutations in colorectal cancer: Relations to patient age, sex and tumour location. Br J Cancer 1994;69:367-71.
7. Brodsky FM, Lem L, Bresnahan PA. Antigen processing and presentation [see comments]. Tissue Antigens 1996;47:464-71.
8. Townsend A, Bodmer FI. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989:7:601-24.
9. Rotzschke O, Falk K, Deres K, et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990:348:252.
10. Eisenloh LC. Yewdell JW, Bennink JR. A transient transfection system for identifying biosynthesized proteins processed an presented to class I MHC restricted T lymphocytes. J Immunol Meth 1992:154:131.
11. Rock KL, Rothstein L, Benacerraf B. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc Natl Acad Sci USA 1992;89:8918-22.
12. Hunt DF, Michel H, Dickinson TA, et al. Peptides presented to the immune system by the murine class II histocompatibility complex molecule I-Ad. Science 1992;256:1817-20.
13. Rudensk AY, Preston-Hulburt P. Hong SC, Barlow A, Janeway CAJ. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991;353:622-7.
14. McKisic MD, Lancki DW, Fitch FW. Cytolytic activity of murine CD4+ T cell clones correlates with gamma IFN production in mouse strains having BALB/c background. J Immunol 1991:150: 3793.
15. Ozdemirli M, El-Khatib L, Bastiani H, Akdeniz H, Kuchroo V, Ju ST. The cytotoxic process of CD4 Thl clones. J Immunol 1992;149:1889-95.
16. Chang JCC, Zhang TL, Edgerton TL, et al. Heterogeneity in direct cytotoxic function of L3T4 T cells: TH1 clones express higher cytotoxic activity to antigen presenting cells than TH2 clones. J Immunol 1990:145:409.
17. Abrams SI, Dobrzanski MJ, Wells DT, et al. Peptide specific activation of cytolytic CD4+ T lymphocytes against tumor cells harboring mutated epitopes of K-ras p21. Eur J Immunol 1995;25:2588-97.
18. Peac DJ, Smith JW, Disis ML. Chen W, Cheever MA. Induction of T cell specific for the mutated segement of the oncogenic p21 ras protein by immunization in vivo with the oncogenic protein. J Immunother 1993;14:110-14.
19. Peace DJ, Smith JW, Chen W. et al. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated Ras peptide. J Exp Med 1994;179:473-9.
20. Skipper J, Stauss HJ. Identification of two cytotoxic T lymphocyte-recognized epotopes in the ras protein. J Exp Med 1993:177: 1493-8.
21. Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogene. J Natl Cancer Inst 1993;85:1294-1302.
22. Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ an CD8+ T cell responses. Eur J Immunol 1996;26:435-43.
23. Fossum B, Olsen AC, Thorsby E, Gaudernack G. CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21 ras derived peptide (13Gly-Asp). are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 1995;40:165-72.
24. Fossum B, Gedde-Dahl III T, Breivik J, et al. p-21 ras-peptide-specific T-cell responses in a patient with colorectal cancer: CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation. Int J Cancer 1994;56:40-5.
25. Tsang KY, Nieroda CA, DeFilippi R, et al. Induction of human cytotoxic T cell lines directed against point-mutated p21 rasderived synthetic peptides. Vaccine Res 1994;3:183-93.
26. Gedd-Dahl TI, Fossum B, Eriksen JA. Thorsby E, Guadernack G. T cell clones specific for p-21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur F Immunol 1993;23:754-60.
27. Van Elsas A, Nijman HW, Van der Minne CE, et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 Ras peptide presented by HLA-A0201. Int J Cancer 1995;61:389-96.
28. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated oncogene ras protein. J Exp Med 1991;73:273-6.
29. Gjertsen MK. Bakka A, Breivik J. et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995:346:1399-1400.
30. Gjertsen MK, Bjorheim J, Saeterdal I. Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997:72:784-90.
31. Sample preparation from paraffin-embeded tissues. In: Wright, Manos, eds. PCR Protocols: A Guide to Methods and Application, 1990:153-8.
32. Abrams SI, Khleif SN. Bergmann-Leitner ES, et al. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with mutated Ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 1997:182:137-51.
33. Gedd-Dahl T, Nelsen E. Thorsby E, Gaudernack G. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant P21 Ras. Cancer Immunol Immunother 1994;38:127-34.
34. Rosenberg SA, Yang JC. Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat Med 1998;4:321-7.